Multi-year clinical study data suggest use of FDA-cleared mobile air
decontamination unit, PlasmairT2006 with HEPA-MD™,
contributes to reducing incidence of airborne aspergillosis infection
Data supports previously reported conclusions in December 2007 issue
of The Journal of Hospital Infection about the benefits of
AirInSpace mobile air filtration devices to help prevent outbreaks of
nosocomial infections related to construction work
WASHINGTON (Business Wire EON) July 2, 2008 --
AirInSpace,
a leading supplier of mobile devices that ‘catch
and inactivate’ harmful and
resistant biological particles from the air, announced today that data
from a multi-year clinical study shows a significant reduction in
aspergillosis infection rates in a standard hospital setting when using
the Company’s patented PlasmairT2006 mobile
unit with HEPA-MD™ technology.
The data were presented by Ludwig
Aho-Glélé, M.D.,
Director of Infection Control and Hospital Epidemiologist at Dijon
University Hospital, a 1600-bed academic teaching hospital in Dijon,
France, during an educational symposium at the recent 2008 annual
conference of the Association for Professionals in Infection Control &
Epidemiology (APIC). The AirInSpace-sponsored symposium, “Strategies
for Airborne Infection Control Under Challenging Environments and
Patient Conditions”, also
included presentations from Michael S. Phillips, M.D.,
Hospital Epidemiologist, Infection Prevention and Control, New York
University (NYU) Medical Center; and, Wayne R. Thomann, Ph.D.,
Director, Occupational and Environmental Safety Office, Duke University
Health System.
“Invasive aspergillosis is a potentially
deadly infection for immune-suppressed hospital patients: the Centers
for Disease Control and Prevention (CDC) reports a mortality rate of 95
percent in immune-suppressed patients who are recipients of allogeneic
bone marrow transplants and patients who have aplastic anemia,”
said Dr. Aho-Glélé.
“These patients need a highly protective
environment. Our multi-year study demonstrates that the AirInSpace
mobile system not only can protect these patients but also is a less
costly solution for our hospital.”
Aspergillus is a genus of some 200, highly airborne molds, some
of which can be deadly, especially to immunocompromised hospital
patients. Incidence rates of invasive aspergillosis have been reported
as high as 26% in allogenic bone marrow transplant patients and 25% in
acute leukemia patients. And in these immunocompromised patients who are
infected by airborne aspergillosis spores, the scientific literature
reports that death occurs in as many as nine out of 10 of these
patients. The cost of extended hospitalization from invasive
aspergillosis is estimated to be as high as $49,336 per case.
“In a hospital setting, construction work
that liberates large amounts of Aspergillus spores is the major
source of nosocomial aspergillosis,” added
Dr. Aho-Glélé. “Given
that we have commenced a major, long-term construction project right
next door to high-risk clinical units such as our adult and pediatric
hematology wards, we need to be extra diligent in preventing liberation
of these spores that are the source of potentially lethal nosocomial
aspergillosis.”
AirInSpace’s flagship product is an
FDA-cleared mobile air-decontamination unit called PlasmairT2006
by AirInSpace. Its performance has been clinically proven to lower
airborne biological loads and is now being used to combat nosocomial
infection in high- risk areas of more than 100 hospitals and clinics,
including hematology/oncology units and ICUs. Developed initially for
use in Russia’s MIR space station, the
AirInSpace technology is in routine use today on the International Space
Station (ISS). AirInSpace owns exclusive rights to this one-of-a-kind
technology, which shows up to 99.999% single-pass inactivation of
airborne microorganisms.
About AirInSpace
Headquartered in Sterling, Va., AirInSpace offers an innovative range of
products and services to address the need for microbial decontamination
of air in hospitals and other environments. For more information, please
visit www.airinspace.com, or
contact the company at: mail@airinspace.com.
Post Comment:
Trackback URL: http://eon.prweb.com/pingpr.php/VGhpci1Db3VwLVRoaXItSGFsZi1FbXB0LVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
